⌕
BridgeBio Pharma · BBIO · Nasdaq
Tenet 43 · Weak
Compare
$76.80−0.72%At closeTenet 43 · Weak
$76.80−0.56 (−0.72%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BridgeBio Pharma (BBIO) Institutional Ownership

13F filers reported holding 54.8% of BridgeBio Pharma (BBIO) shares as of Sep 30, 2026, across 351 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
54.8%
Sep 30, 2026
13F filers
351
quarter ended Sep 30, 2026
13F value
$7.0B
106.7M shares
Quarter's fund flow
Mild accumulation
50 new · 53 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (50 new · 142 increased · 106 reduced · 53 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 351 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Aug 19, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale8,100$83.86↗
Aug 19, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale1,800$84.69↗
Aug 19, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale100$85.65↗
Aug 18, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale1,900$81.15↗
Aug 18, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale17,279$82.21↗
Aug 18, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale14,602$82.99↗
Aug 18, 2026Kumar NeilChief Executive OfficerDisposed · Open-market sale1,199$83.77↗
Aug 16, 2026Trimarchi ThomasPresident and CFODisposed · Tax withholding22,781$79.86↗
Aug 16, 2026Kumar NeilChief Executive OfficerAcquired · Option exercise33,544—↗
Aug 16, 2026Kumar NeilChief Executive OfficerAcquired · Option exercise19,599—↗
Aug 16, 2026Kumar NeilChief Executive OfficerAcquired · Option exercise11,554—↗
Aug 16, 2026Kumar NeilChief Executive OfficerAcquired · Option exercise6,520—↗
Aug 16, 2026Kumar NeilChief Executive OfficerDisposed · Tax withholding36,237$79.86↗
Aug 16, 2026Kumar NeilChief Executive OfficerDisposed · Option exercise33,544Restricted Stock Units—↗
Aug 16, 2026Kumar NeilChief Executive OfficerDisposed · Option exercise19,599Restricted Stock Units—↗
Aug 16, 2026Kumar NeilChief Executive OfficerDisposed · Option exercise11,554Restricted Stock Units—↗
Aug 16, 2026Kumar NeilChief Executive OfficerDisposed · Option exercise6,520Restricted Stock Units—↗
Aug 16, 2026Apuli MaricelChief Accounting OfficerDisposed · Tax withholding4,714$79.86↗
Jul 30, 2026Apuli MaricelChief Accounting OfficerDisposed · Open-market sale2,000$80.06↗
Jul 9, 2026Ellis AndreadirectorAcquired · Option exercise17,167$16.75↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of BridgeBio Pharma do institutions hold?

13F filers reported holding 54.8% of BridgeBio Pharma's shares as of Sep 30, 2026, across 351 filers.

How many 13F filers hold BridgeBio Pharma?

BridgeBio Pharma was held by 351 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.